Fennec Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Fennec Pharmaceuticals has a total shareholder equity of $-5.2M and total debt of $32.1M, which brings its debt-to-equity ratio to -620.7%. Its total assets and total liabilities are $58.9M and $64.1M respectively. Fennec Pharmaceuticals's EBIT is $1.7M making its interest coverage ratio 0.6. It has cash and short-term investments of $40.3M.
Key information
-620.7%
Debt to equity ratio
US$32.10m
Debt
| Interest coverage ratio | 0.6x |
| Cash | US$40.32m |
| Equity | -US$5.17m |
| Total liabilities | US$64.09m |
| Total assets | US$58.92m |
Recent financial health updates
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
Jul 16
Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans
May 26Recent updates
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Nov 24Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
Oct 04Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Aug 15Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
Jul 16Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
Jun 02Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children
Sep 20Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Aug 23Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor
Aug 01Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Oct 29Fennec Could See Upside If Pedmark Gets Approved
Jul 29Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
Jun 18Fennec Pharma resubmits PEDMARK application in U.S.
May 28Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans
May 26Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 01Financial Position Analysis
Short Term Liabilities: FENC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: FENC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: FENC has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: FENC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable FENC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: FENC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 15.4% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 23:36 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fennec Pharmaceuticals Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| Naureen Quibria | Capital One Securities, Inc. |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |